



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

ART
Advanced Radiation
Therapy

OMICS APPLIED TO HOST RESPONSE: METHODS AND GENERAL APPLICATIONS

Antonella Sistigu, PhD

Department of Translational Medicine and Surgery


Università Cattolica del Sacro Cuore



**MODERN RADIATION ONCOLOGY:
MULTIDISCIPLINARITY IN THE ERA
OF OMICS AND AI GUIDED ONCOLOGY**
32° RESIDENTIAL COURSE


17-19 October, 2022

Cancer immunoediting and response to immunotherapy



A deep understanding of tumor-host interaction and co-evolution is needed to make immunotherapy a precise application in the clinical setting

High dimensional omics in immuno-oncology



omics and tumor microenvironment (TME)





Figure adapted from Wagner, Nat Biotech, 2016

omics and TME: cellular composition

Omics profiling technologies in immuno-oncology



omics and TME: cellular composition

- ✓ HCC patients > nivolumab
- ✓ PDAC patients > GVAX+ipilimumab
- ✓ Melanoma patients > ipilimumab





Figure adapted from Sidiropoulos, JCI, 2022

RNA-seq+WGS/WES

✓ to predict patient-specific cancer immunogenic neoantigens



LETTER

doi:10.1038/nature21003

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Ugur Sahin^{1,2,3}, Evelyn Derhovancsian¹, Matthias Müller¹, Björn-Philipp Kiske¹, Petra Simon¹, Martin Löber¹, Valeria Bakiri^{1,2}, Arbel D. Tadmor¹, Ulrich Luxemburger¹, Barbara Scheer¹, Tania Omokoko¹, Matthias Voemela Anna Paruzynski¹, Andreas N. Kuhn¹, Janina Buck¹, Sandra Blesch¹, Katharina H. Schösch¹, Isabel Vogler¹, Eva Godelhardt¹, Sebastian Artig^{1,4}, Richard Rae¹, Andrea Bechtold¹, Claudia T. Goran Martić¹, Alexander Hübner¹, Patrick Sorn¹, Jan Diekmann¹, Jasjo Ciesla¹, Olga Wal Alexandra-Kemmer Brück¹, Meike Witt¹, Martina Zilgen¹, Andreas Rothermel¹, Barbara Kauer Stefanie Rohle¹, Mustafa Diken^{1,2}, Sebastian Kreier^{1,1}, Romina Nemesek¹, Christoffer Gebauer Christoph Hüller¹, Achim Uthoff^{1,2}, Christoph Huber^{1,2,3}, Carmen Lopez^{1,4} & Özlem Türeci^{1,2}

LETTER



doi:10.1038/nature21981

An immunogenic personal neoantigen vaccine for patients with melanoma

Patrick A. Ott^{1,2,3}, Zhiting He^{1,4}, Derin B. Keskin^{1,2,4}, Sachet A. Shukla^{1,4}, Jing Sun¹, David I. Bozym¹, Wandi Zhang¹, Adrienne Luoma¹, Anita Giobbie-Harder¹, Lauren Peter^{1,2,4}, Christina Chen¹, Ovid Ollivier¹, Todd A. Carter¹, Shaoqiang Li¹, David J. Lieb¹, Thomas Eisenhauer¹, Evina Gjini¹, Jonathan Stevens^{1,5}, William I. Lane^{1,6}, Indu Iyer^{1,4}, Kallappanadar Nellaiappan¹, Andres M. Salazar¹, Heather Daley¹, Michael Seaman¹, Elizabeth E. Buchbinder^{1,2,3}, Charles H. Yoon^{1,2}, Morgan Harder¹, Niall Lennon¹, Stacey Gabriel¹, Scott L. Rodig^{1,2,3}, Dan H. Barouch^{1,2,4}, Jon C. Aster^{1,2}, Gad Getz^{1,2,4}, Kai Wucherpfennig^{1,3}, Donna Neuberg¹, Jerome Ritz^{1,2,3}, Eric S. Lander^{1,4}, Edward F. Fritschy^{1,4}, Nir Hacohen^{1,2,4,5} & Catherine I. Wu^{1,2,4}

RNA-seq

✓ to quantify different cell types of the TME (G)



Finotello *et al. Genome Medicine* (2019) 11:34
<https://doi.org/10.1186/s13073-019-0638-6>

Genome Medicine

METHOD

Open Access

Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data



Cancer Therapy: Clinical

Clinical
Cancer
Research

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire


Lidia Robert¹, Jennifer Tsoi², Xiaoyan Wang^{1,3}, Ryan Emerson^{7,8}, Blanca Homet^{1,9}, Thinle Chodon¹, Stephen Mok^{1,2}, Rong Rong Huang⁴, Alistair J. Cochran⁴, Begoña Comin-Anduix^{5,6}, Richard C. Koya^{5,6}, Thomas G. Graeber^{2,6}, Harlan Robins^{7,8}, and Antoni Ribas^{1,2,5,6}

Cell

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab





Nadeem Riaz,^{1,2,3,15} Jonathan J. Havel,^{1,15} Vladimir Makarov,^{1,3,15} Alexis Desrichard,^{1,15} Walter J. Urba,⁴ Jennifer S. Sims,^{1,3} F. Stephen Hodi,⁵ Salvador Martin-Algarra,⁶ Rajarsi Mandal,⁷ William H. Sharfman,⁸ Shailender Bhatia,⁹ Wen-Jen Hwu,¹⁰ Thomas F. Gajewski,¹¹ Craig L. Slingluff, Jr.,¹² Diego Chowell,^{1,3} Sviatoslav M. Kendall,^{1,3} Han Chang,¹³ Rachna Shah,¹ Fengshen Kuo,³ Luc G.T. Morris,^{3,7} John-William Sidhom,¹⁴ Jonathan P. Schneck,¹⁴ Christine E. Horak,¹³ Nils Weinhold,^{2,*} and Timothy A. Chan^{1,2,3,16,*}

Paired mRNA and TCR analysis



OPEN Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

Structure and histone modification




RNA-seq+ATAC-seq/CHIP-seq

- ✓ this intra-modality integration is allowing researchers to build the tumor immune atlas, that provide a comprehensive compendium of immune cells and an inspection of gene expression patterns in different immune cell types within the TME



HUMAN CELL ATLAS
IMMUNE SYSTEM

From the Human Cell Atlas to dynamic immune maps in human disease



The relative spatial distribution of cells impacts therapeutic response




Figure adapted from Galon Nat Rev Drug Discov, 2019

High dimensional spatial proteomics

- ✓ Image mass cytometry (IMC)
- ✓ Multiplexed ion beam imaging
- ✓ Cyclic imaging detection (CODEX)
- ✓ Cyclic immunofluorescence (CyCIF)
- ✓ Multiplexed immunofluorescence (MxIF)


High dimensional spatial transcriptomics

- ✓ Slide-seq
- ✓ 10X Genomics Visium
- ✓ Sequential fluorescence *in situ* hybridization (seqFISH)
- ✓ MERFISH




omics and TME: spatial distribution

The relative spatial distribution of cells impacts therapeutic response

Nonresponders



Responders




HCC patients treated with cabozantinib+nivolumab

Figure adapted from Ho Nat Cancer, 2021


omics and TME: spatial distribution

The immuno *SpatialScore*


Cell-cell interactions impact on tumor's (immune)therapeutic response



SpatialScore distance ratio = Right / Left



SpatialScore = T cell effector / suppressive activity




Cutaneous T cell lymphoma patients treated with pembrolizumab

Figure adapted from Phillips Nat Commun 2021

omics and TME: spatial distribution

Spatial multi-omics for precision immuno-oncology

Spatial multi-omics help to reveal patient –specific TMEs enabling personalized therapies



Tumor-immune interactions during (immuno)therapeutic response are dynamic

TCR/BCR-seq

- ✓ to follow clonal evolution and immuno dominance during cancer progression and response to (immuno)therapy







Figure adapted from Pagliuca, JCI, 2021

Tumor-immune interactions during (immune)therapeutic response are dynamic

Cancer Stem
Cancer Progenitor
Cancer Senescence
CD8+ T effector
CD8+ T Cytotoxic
CD8+ T exhausted
CD4+ FOXP3+ T Cell
MDSC



Conclusions

- ✓ Therapeutic response and resistance depends on the cellular composition of tumors and their microenvironments, the spatial distribution of cells and the cellular evolution over time.
- ✓ Bulk and single cell omics together with emerging spatial molecular technologies are ideally suited to resolve the molecular and cellular mechanisms of therapeutic response and resistance.
- ✓ Integrating mathematical modeling with multi-omics can model intercellular networks and co-evolution over time, which finally tip the balance between therapy response or resistance.

Thank you for the attention!